alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 12 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington's disease is a dominantly inherited, progressive neurodegenerative disorder causing marked pathology in the basal ganglia." | 1.28 | Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. ( Dure, LS; Penney, JB; Young, AB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolodziejczyk, K | 1 |
| Parsons, MP | 1 |
| Southwell, AL | 1 |
| Hayden, MR | 2 |
| Raymond, LA | 1 |
| Ortiz, AN | 1 |
| Kurth, BJ | 1 |
| Osterhaus, GL | 1 |
| Johnson, MA | 1 |
| Simmons, DA | 1 |
| Mehta, RA | 1 |
| Lauterborn, JC | 1 |
| Gall, CM | 1 |
| Lynch, G | 1 |
| André, VM | 1 |
| Cepeda, C | 2 |
| Venegas, A | 1 |
| Gomez, Y | 1 |
| Levine, MS | 2 |
| Wagster, MV | 1 |
| Hedreen, JC | 1 |
| Peyser, CE | 1 |
| Folstein, SE | 1 |
| Ross, CA | 1 |
| Kremer, B | 1 |
| Tallaksen-Greene, SJ | 1 |
| Albin, RL | 1 |
| Calabresi, P | 1 |
| Centonze, D | 1 |
| Pisani, A | 1 |
| Sancesario, G | 1 |
| Gubellini, P | 1 |
| Marfia, GA | 1 |
| Bernardi, G | 1 |
| Canals, JM | 1 |
| Marco, S | 1 |
| Checa, N | 1 |
| Michels, A | 1 |
| Pérez-Navarro, E | 1 |
| Arenas, E | 1 |
| Alberch, J | 1 |
| Ariano, MA | 1 |
| Calvert, CR | 1 |
| Flores-Hernández, J | 1 |
| Chandler, SH | 1 |
| Leavitt, BR | 1 |
| Cotton, P | 1 |
| Dure, LS | 1 |
| Young, AB | 1 |
| Penney, JB | 1 |
| Beal, MF | 1 |
| Ferrante, RJ | 1 |
| Swartz, KJ | 1 |
| Kowall, NW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930] | Phase 2 | 25 participants | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; CA1 Region, Hippocampal; Cell Mem | 2014 |
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; alpha-Methyltyrosine; Animals; Biophysics; | 2010 |
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Dyskinesia Agents; Corpus St | 2011 |
Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Barium; Benzothiadiazines; Cerebr | 2006 |
Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Autoradiography; Frontal Lobe; Humans; Hun | 1994 |
AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: implications for Huntington's disease.
Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Glutamates; Glutamic Acid; Humans; H | 1993 |
Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain Ischemia; Cells, Cultured; | 1998 |
Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain-Derived Neurotrophic Factor | 1998 |
NMDA receptor function in mouse models of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Calcium Channel | 2001 |
Neuroscientists begin to piece together more parts of Huntington's disease puzzle.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain Chemistry; Dise | 1992 |
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
Topics: Adolescent; Adult; Age Factors; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Bind | 1991 |
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra | 1991 |